+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Colchicine Market by Indication, Formulation, Route, End User, Distribution Channel, Dosage - Global Forecast to 2030- Product Image
Colchicine Market by Indication, Formulation, Route, End User, Distribution Channel, Dosage - Global Forecast to 2030- Product Image
Sale

Colchicine Market by Indication, Formulation, Route, End User, Distribution Channel, Dosage - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967649
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Colchicine Market grew from USD 1.58 billion in 2024 to USD 1.71 billion in 2025. It is expected to continue growing at a CAGR of 7.86%, reaching USD 2.49 billion by 2030.

Setting the Stage for Colchicine’s Market Evolution

Colchicine has long stood as a cornerstone therapeutic for inflammatory conditions, tracing its origins back centuries to the treatment of gout. Today, it commands renewed attention across a broader spectrum of indications, including Behçet’s Disease, Familial Mediterranean Fever, and pericarditis, owing to its potent anti-inflammatory properties and well-defined safety profile. Its versatility and cost-effectiveness continue to drive adoption in clinical practice, while ongoing research explores novel applications and optimized dosing strategies.

This executive summary distills critical developments shaping the colchicine landscape, offering decision-makers an authoritative overview of market dynamics, regulatory shifts and competitive activity. By examining transformative trends, tariff implications, segmentation nuances, regional variations, company strategies and actionable recommendations, this document equips stakeholders with the context and foresight needed to navigate an evolving environment. Whether refining a product portfolio, evaluating partnership potential or realigning commercial tactics, readers will discover a coherent synthesis of the factors driving the next phase of growth in the colchicine market.

Emerging Trends Shaping the Next Generation of Therapies

The colchicine landscape is undergoing a paradigm shift as precision medicine and value-based care models gain traction. Novel formulations and delivery technologies are enhancing patient adherence, particularly through extended-release oral tablets and targeted parenteral options that optimize pharmacokinetics. These advances are redefining treatment paradigms for gout prophylaxis and expanding opportunities within rare autoinflammatory disorders.

Simultaneously, payer frameworks are evolving to reward outcomes and cost efficiency, prompting manufacturers to demonstrate real-world effectiveness and pharmacoeconomic value. This shift has incentivized the development of low-dose regimens that maintain clinical efficacy while reducing adverse events and overall healthcare costs. The competitive arena is also intensifying as biosimilars and generic entries challenge established brands, leading to strategic alliances and licensing agreements to consolidate market share.

These transformative shifts underscore the importance of agility in product innovation, reimbursement strategy and stakeholder engagement. Companies that invest in differentiated delivery systems, robust evidence generation and collaborative reimbursement models will be uniquely positioned to capture emerging segments and drive superior patient outcomes.

Navigating Tariff-Driven Cost Pressures in 2025

In 2025, adjustments to United States tariff structures have introduced significant cost pressures across raw materials, packaging components and active pharmaceutical ingredients. With a cumulative tariff adjustment exceeding 15 percent for key inputs, manufacturers have been compelled to reassess supply chain strategies and pricing models. The impact has been most pronounced for firms reliant on parenteral-grade excipients sourced from international suppliers subject to heightened duties.

These increased import costs have led some producers to diversify sourcing toward regional suppliers, although capacity constraints and quality certifications have limited the pace of transition. As a result, a subset of market participants has absorbed additional expenses, squeezing margins and prompting the renegotiation of contracts with distributors. Others have initiated targeted price adjustments for oral tablet formulations, balancing profitability with competitive positioning.

Looking ahead, continued dialogue with regulatory bodies and trade negotiators will be critical to mitigate tariff volatility. Companies that proactively optimize inventories, invest in domestic manufacturing capabilities and refine cost pass-through mechanisms will fortify resilience against shifting trade dynamics.

Decoding the Multifaceted Segmentation Landscape

Analysis of the colchicine market through the lens of therapeutic application reveals that gout remains a primary revenue driver, closely followed by pericarditis where intravenous and intramuscular injections address acute clinical needs. In contrast, rare autoinflammatory conditions such as Behçet’s Disease and Familial Mediterranean Fever, while representing smaller patient populations, exhibit higher per-patient value and long-term treatment engagement.

Examining dosage forms uncovers a growing preference for oral capsules in routine management, whereas extended-release tablets are gaining adoption for patients requiring stable plasma concentrations. Injectable formulations continue to play a pivotal role in hospital and clinic settings, particularly for acute flare interventions. The oral and parenteral administration routes each command distinct market shares, with oral dominated by standard and extended-release tablets, and parenteral distributed between intramuscular and intravenous options.

Assessment by end user indicates that hospitals capture significant volume through acute care protocols, while home care settings increasingly support self-administered oral regimens, reducing inpatient stays. Distribution channels reflect a balanced ecosystem: hospital pharmacies maintain central procurement roles, retail pharmacies-both chain and independent-cater to outpatient demands, and online platforms, including direct-to-consumer portals and partner websites, extend patient reach. Dosage strengths spanning low, standard and high regimens meet diverse clinical requirements, with the highest dose segments commanding premium pricing and lower dose tiers offering broader formulary access.

Regional Dynamics Driving Divergent Growth Trajectories

The Americas region continues to dominate global colchicine consumption, driven by mature markets with established treatment guidelines, robust payer frameworks and high prevalence of gout. Regulatory pathways in North America encourage label expansions, bolstering life cycle management strategies. Latin American markets, while smaller, present growth potential through increasing disease awareness and improving healthcare infrastructure.

In Europe, Middle East & Africa, variances in reimbursement policies and regulatory harmonization influence market entry and pricing. Western European countries demonstrate stable uptake of extended-release formulations, whereas emerging markets in the Middle East and Africa are adopting generics rapidly to meet affordability goals. Parallel import mechanisms and local manufacturing initiatives are reshaping competitive dynamics across this broad territory.

Asia-Pacific showcases the fastest compound annual growth driven by rising incidence of cardiometabolic disorders and expanding access to specialty care. Countries such as China, Japan and Australia are advancing biosimilar pathways and incentivizing localized production. Southeast Asian nations are gradually improving cold chain logistics, facilitating greater penetration of parenteral offerings, while home care trends are boosting demand for oral delivery methods.

Strategic Moves by Industry Leaders

Leading pharmaceutical companies are intensifying investments in formulation innovation, patent extensions and strategic collaborations with contract manufacturing organizations. Several firms have secured exclusivity on extended-release tablet technologies, leveraging proprietary polymer matrices to differentiate against generic competition. Others are forging partnerships to access emerging markets, combining global regulatory expertise with local commercial networks.

Recent mergers and acquisitions have consolidated capabilities in biopharmaceutical development, with top-tier organizations integrating biologics platforms to explore combination therapies that enhance colchicine’s efficacy. Meanwhile, specialty drug manufacturers are focusing on orphan indications, aligning with regulatory incentives and orphan drug exclusivity periods to maximize returns.

Supply chain optimization has become a priority as well, with leading players implementing advanced analytics and digital traceability to ensure quality and reduce lead times. Those at the forefront of adopting artificial intelligence for demand planning and risk management are achieving more resilient operations and improved service level agreements with distributors and healthcare providers.

High-Impact Strategies for Market Leadership

Industry leaders should prioritize targeted investments in novel delivery mechanisms that enhance patient adherence and differentiate offerings. Collaborating with clinical investigators to generate real-world evidence and health economic data will support payer negotiations and reinforce value-based contracts. Companies should also explore licensing agreements in emerging markets to mitigate tariff exposure and expand geographic reach.

Developing agile supply chains through dual sourcing strategies and regional manufacturing hubs will buffer against trade disruptions and cost fluctuations. Organizations are encouraged to deploy predictive analytics tools to anticipate raw material shortages and optimize inventory levels. Engaging directly with patient advocacy groups and key opinion leaders will bolster market acceptance, particularly for low-prevalence indications that require specialized awareness campaigns.

Embracing digital marketing channels and telemedicine partnerships can further drive volume and adherence in home care settings, reducing reliance on inpatient administration. Establishing cross-functional task forces that unite commercial, medical affairs and regulatory teams will ensure cohesive execution of product life cycle strategies and accelerate time to market for incremental innovations.

Methodical Approach Ensuring Data Integrity

This report synthesizes data from a comprehensive review of peer-reviewed journals, clinical trial registries and regulatory filings. Primary research includes structured interviews with pharmaceutical executives, healthcare practitioners and payers to capture qualitative insights on market trends, unmet needs and adoption barriers. Secondary research involved analysis of proprietary databases, trade publications and governmental sources to verify pricing, reimbursement policies and tariff regulations.

Quantitative data have been triangulated through cross-referencing shipment volumes, prescription records and public import/export statistics. Forecast assumptions were validated by expert advisory panels comprised of rheumatologists, cardiologists and pharmacoeconomists. Segmentation definitions align with standardized anatomical therapeutic chemical classifications and dosage form categorizations employed by global health authorities.

Findings were subjected to rigorous quality assurance protocols, including peer review by an internal methodology oversight team. Any data discrepancies or anomalies were resolved through follow-up inquiries and calibration against benchmark studies. The result is a robust, transparent framework that underpins the credibility and actionability of the market insights presented herein.

Synthesizing Insights to Chart the Path Forward

This executive summary has distilled the multifaceted dynamics shaping the global colchicine market, from evolving therapeutic applications and cost pressures to nuanced segmentation and regional disparities. Collectively, these insights illuminate the strategies required to thrive in a competitive landscape marked by tariff volatility, generic encroachment and shifting payer demands.

By aligning product portfolios with patient-centric delivery formats, optimizing supply chains for resilience and forging strategic alliances that leverage local expertise, stakeholders can unlock new growth avenues. The integration of real-world evidence and digital engagement models will further solidify market positions and enhance patient outcomes. Ultimately, success will hinge on the ability to anticipate changes, adapt swiftly and execute with precision.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Behçet’s Disease
    • Familial Mediterranean Fever
    • Gout
    • Pericarditis
  • Formulation
    • Injectable
      • Intramuscular
      • Intravenous
    • Oral Capsule
    • Oral Tablet
      • Extended Release
      • Standard Release
  • Route
    • Oral
    • Parenteral
      • Intramuscular
      • Intravenous
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
      • Direct-to-Consumer
      • Partner Platforms
    • Retail Pharmacy
      • Chain
      • Independent
  • Dosage
    • High Dose
      • 1.8 mg
      • 2.4 mg
    • Low Dose
      • 0.3 mg
      • 0.6 mg
    • Standard Dose
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Limited
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Limited
  • Lupin Limited
  • Dr. Reddy's Laboratories Limited
  • Cipla Limited
  • Apotex Inc.
  • Hetero Drugs Limited
  • Torrent Pharmaceuticals Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Colchicine Market, by Indication
8.1. Introduction
8.2. Behçet’s Disease
8.3. Familial Mediterranean Fever
8.4. Gout
8.5. Pericarditis
9. Colchicine Market, by Formulation
9.1. Introduction
9.2. Injectable
9.2.1. Intramuscular
9.2.2. Intravenous
9.3. Oral Capsule
9.4. Oral Tablet
9.4.1. Extended Release
9.4.2. Standard Release
10. Colchicine Market, by Route
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.3.1. Intramuscular
10.3.2. Intravenous
11. Colchicine Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Colchicine Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.3.1. Direct-to-Consumer
12.3.2. Partner Platforms
12.4. Retail Pharmacy
12.4.1. Chain
12.4.2. Independent
13. Colchicine Market, by Dosage
13.1. Introduction
13.2. High Dose
13.2.1. 1.8 mg
13.2.2. 2.4 mg
13.3. Low Dose
13.3.1. 0.3 mg
13.3.2. 0.6 mg
13.4. Standard Dose
14. Americas Colchicine Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Colchicine Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Colchicine Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Teva Pharmaceutical Industries Limited
17.3.2. Sandoz International GmbH
17.3.3. Viatris Inc.
17.3.4. Sun Pharmaceutical Industries Limited
17.3.5. Lupin Limited
17.3.6. Dr. Reddy's Laboratories Limited
17.3.7. Cipla Limited
17.3.8. Apotex Inc.
17.3.9. Hetero Drugs Limited
17.3.10. Torrent Pharmaceuticals Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. COLCHICINE MARKET MULTI-CURRENCY
FIGURE 2. COLCHICINE MARKET MULTI-LANGUAGE
FIGURE 3. COLCHICINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL COLCHICINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL COLCHICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL COLCHICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COLCHICINE MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COLCHICINE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COLCHICINE MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COLCHICINE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COLCHICINE MARKET SIZE, BY ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COLCHICINE MARKET SIZE, BY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL COLCHICINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL COLCHICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL COLCHICINE MARKET SIZE, BY DOSAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL COLCHICINE MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS COLCHICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS COLCHICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES COLCHICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES COLCHICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC COLCHICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC COLCHICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. COLCHICINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. COLCHICINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. COLCHICINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COLCHICINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL COLCHICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL COLCHICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL COLCHICINE MARKET SIZE, BY BEHÇET’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL COLCHICINE MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL COLCHICINE MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL COLCHICINE MARKET SIZE, BY PERICARDITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL COLCHICINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL COLCHICINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL COLCHICINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL COLCHICINE MARKET SIZE, BY ORAL CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL COLCHICINE MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL COLCHICINE MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL COLCHICINE MARKET SIZE, BY STANDARD RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL COLCHICINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL COLCHICINE MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL COLCHICINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL COLCHICINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL COLCHICINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL COLCHICINE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL COLCHICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL COLCHICINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL COLCHICINE MARKET SIZE, BY DIRECT-TO-CONSUMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL COLCHICINE MARKET SIZE, BY PARTNER PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL COLCHICINE MARKET SIZE, BY CHAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL COLCHICINE MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL COLCHICINE MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL COLCHICINE MARKET SIZE, BY 1.8 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL COLCHICINE MARKET SIZE, BY 2.4 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL COLCHICINE MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL COLCHICINE MARKET SIZE, BY 0.3 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL COLCHICINE MARKET SIZE, BY 0.6 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL COLCHICINE MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS COLCHICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES COLCHICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 79. CANADA COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 81. CANADA COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 82. CANADA COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 83. CANADA COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 84. CANADA COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 85. CANADA COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. CANADA COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. CANADA COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 88. CANADA COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 89. CANADA COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 90. CANADA COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 91. CANADA COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 92. MEXICO COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. MEXICO COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 96. MEXICO COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 97. MEXICO COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 98. MEXICO COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. MEXICO COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. MEXICO COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 102. MEXICO COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA COLCHICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 158. GERMANY COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. GERMANY COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. GERMANY COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 161. GERMANY COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 162. GERMANY COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 163. GERMANY COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 164. GERMANY COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. GERMANY COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. GERMANY COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 167. GERMANY COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 168. GERMANY COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 169. GERMANY COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 170. GERMANY COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. FRANCE COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 173. FRANCE COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 174. FRANCE COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 175. FRANCE COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 176. FRANCE COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 177. FRANCE COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. FRANCE COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. FRANCE COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 180. FRANCE COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 181. FRANCE COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 182. FRANCE COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 183. FRANCE COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 197. ITALY COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. ITALY COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 199. ITALY COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 200. ITALY COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 201. ITALY COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 202. ITALY COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 203. ITALY COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. ITALY COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. ITALY COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 206. ITALY COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 207. ITALY COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 208. ITALY COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 209. ITALY COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 210. SPAIN COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. SPAIN COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 214. SPAIN COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 215. SPAIN COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 216. SPAIN COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. SPAIN COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. SPAIN COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 219. SPAIN COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 220. SPAIN COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 221. SPAIN COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 222. SPAIN COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 262. DENMARK COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 263. DENMARK COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 264. DENMARK COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 265. DENMARK COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 266. DENMARK COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 267. DENMARK COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 268. DENMARK COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. DENMARK COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. DENMARK COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 271. DENMARK COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 272. DENMARK COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 273. DENMARK COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 274. DENMARK COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 288. QATAR COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. QATAR COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 290. QATAR COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 291. QATAR COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 292. QATAR COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 293. QATAR COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 294. QATAR COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. QATAR COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. QATAR COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 297. QATAR COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 298. QATAR COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 299. QATAR COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 300. QATAR COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 301. FINLAND COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. FINLAND COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 303. FINLAND COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 304. FINLAND COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 305. FINLAND COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 306. FINLAND COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 307. FINLAND COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. FINLAND COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. FINLAND COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 310. FINLAND COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 311. FINLAND COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 312. FINLAND COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 313. FINLAND COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 314. SWEDEN COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 315. SWEDEN COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 316. SWEDEN COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 318. SWEDEN COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 319. SWEDEN COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 320. SWEDEN COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. SWEDEN COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 327. NIGERIA COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 338. NIGERIA COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 340. EGYPT COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 341. EGYPT COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 342. EGYPT COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 343. EGYPT COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 344. EGYPT COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 345. EGYPT COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 346. EGYPT COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 347. EGYPT COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 348. EGYPT COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 349. EGYPT COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 350. EGYPT COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 351. EGYPT COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 352. EGYPT COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 353. TURKEY COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 354. TURKEY COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 355. TURKEY COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 356. TURKEY COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 357. TURKEY COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 358. TURKEY COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 359. TURKEY COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 360. TURKEY COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 361. TURKEY COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 362. TURKEY COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 363. TURKEY COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 364. TURKEY COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 365. TURKEY COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 366. ISRAEL COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 367. ISRAEL COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 368. ISRAEL COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 369. ISRAEL COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 370. ISRAEL COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 371. ISRAEL COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 372. ISRAEL COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 373. ISRAEL COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 374. ISRAEL COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 375. ISRAEL COLCHICINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 376. ISRAEL COLCHICINE MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 377. ISRAEL COLCHICINE MARKET SIZE, BY HIGH DOSE, 2018-2030 (USD MILLION)
TABLE 378. ISRAEL COLCHICINE MARKET SIZE, BY LOW DOSE, 2018-2030 (USD MILLION)
TABLE 379. NORWAY COLCHICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 380. NORWAY COLCHICINE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 381. NORWAY COLCHICINE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 382. NORWAY COLCHICINE MARKET SIZE, BY ORAL TABLET, 2018-2030 (USD MILLION)
TABLE 383. NORWAY COLCHICINE MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 384. NORWAY COLCHICINE MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 385. NORWAY COLCHICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 386. NORWAY COLCHICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 387. NORWAY COLCHICINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 38

Companies Mentioned

The companies profiled in this Colchicine market report include:
  • Teva Pharmaceutical Industries Limited
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Limited
  • Lupin Limited
  • Dr. Reddy's Laboratories Limited
  • Cipla Limited
  • Apotex Inc.
  • Hetero Drugs Limited
  • Torrent Pharmaceuticals Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.71 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.49 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

2025 Colchicine Market Outlook Report: Industry Size, Market Shares Data, Insights, Growth Trends, Opportunities, Competition 2024 to 2032 - Product Image

2025 Colchicine Market Outlook Report: Industry Size, Market Shares Data, Insights, Growth Trends, Opportunities, Competition 2024 to 2032

  • Report
  • 144 Pages
  • Global
From
Colchicine (CAS 64-86-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Colchicine (CAS 64-86-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Colchicine Salicylate (CAS 8013-62-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Colchicine Salicylate (CAS 8013-62-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Pericarditis Drugs - Global Strategic Business Report - Product Image

Pericarditis Drugs - Global Strategic Business Report

  • Report
  • 289 Pages
  • Global
From
Acute Myocardial Infarction - Market Insights, Epidemiology and Market Forecast - 2034 - Product Image

Acute Myocardial Infarction - Market Insights, Epidemiology and Market Forecast - 2034

  • Report
  • 244 Pages
  • Global
From

About the Colchicine Market

Colchicine is a medication used to treat and prevent gout and other inflammatory conditions. It is a member of the cardiovascular drug class, which includes drugs used to treat and prevent heart and blood vessel diseases. Colchicine works by reducing inflammation and swelling, and is often used to treat acute gout attacks. It is also used to treat familial Mediterranean fever, pericarditis, and Behcet's disease. Colchicine is available in both oral and injectable forms, and is typically taken once or twice a day. Common side effects include nausea, vomiting, and diarrhea. Serious side effects include liver damage, kidney failure, and bone marrow suppression. The colchicine market is highly competitive, with many generic and branded products available. Companies in the market include Mylan, Teva Pharmaceuticals, Sandoz, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.